St. John's Wort and Lithium: Not Safe to Combine
Do not combine St. John's wort with lithium therapy. While the FDA lithium label does not explicitly list St. John's wort as a contraindicated drug interaction, the combination poses significant safety concerns through both pharmacokinetic and pharmacodynamic mechanisms that can lead to serious adverse outcomes.
Primary Safety Concerns
Drug Interaction Mechanisms
St. John's wort is a potent inducer of CYP3A4 and P-glycoprotein 1, 2, 3. This induction capability creates two critical problems when combined with lithium:
Unpredictable lithium levels: While lithium is primarily renally excreted and not metabolized by CYP enzymes 4, the addition of St. John's wort to a stable lithium regimen introduces metabolic changes that can affect overall drug clearance and therapeutic stability
Serotonin syndrome risk: Both lithium (which has serotonergic effects) and St. John's wort (which acts as a serotonin reuptake inhibitor) can increase serotonergic activity. When combined with other serotonergic agents, St. John's wort has caused serotonin syndrome 3, 5, 6
Lithium's Narrow Therapeutic Window
The FDA label emphasizes that lithium has an extremely narrow therapeutic index 4. Key monitoring requirements include:
- Lithium toxicity signs: diarrhea, vomiting, tremor, mild ataxia, drowsiness, muscular weakness 4
- The therapeutic window is so narrow that even minor changes in clearance or drug interactions can precipitate toxicity
- Patients must maintain normal diet, salt intake, and adequate fluid intake (2500-3000 mL) during stabilization 4
Clinical Evidence Against Combination
Documented Interaction Profile
St. John's wort has demonstrated clinically significant interactions with numerous medications through CYP3A4 and P-glycoprotein induction 1, 2. Documented interactions include:
- Decreased blood concentrations of: cyclosporine (leading to organ rejection), digoxin, warfarin, oral contraceptives (causing breakthrough bleeding and unplanned pregnancies), and multiple other drugs 3, 7
- Drugs with narrow therapeutic indices require closer monitoring when St. John's wort is added, discontinued, or dosage changed 7
Pharmacodynamic Concerns
Beyond pharmacokinetic interactions, St. John's wort poses pharmacodynamic risks when combined with other psychotropic medications:
- Serotonin syndrome has been reported when St. John's wort was combined with SSRIs (sertraline, paroxetine) and other serotonergic agents 3, 5
- The combination of St. John's wort with serotonergic agents "should be restricted to prescription-only, by experienced clinicians, due to potential central pharmacodynamic interactions" 7
Effectiveness Considerations
Even if safety could be assured, the effectiveness of this combination is questionable:
- St. John's wort's antidepressant efficacy is primarily established for mild-to-moderate depression 2, 6, 8
- Evidence regarding St. John's wort as stand-alone treatment compared with standard antidepressants "has yet to be proven conclusively" 6
- Lithium is typically used for bipolar disorder or treatment-resistant depression—conditions requiring more robust interventions than St. John's wort provides
Clinical Recommendations
If a patient on lithium is considering or already taking St. John's wort:
- Discontinue St. John's wort immediately and do not initiate this combination
- Monitor lithium levels closely if St. John's wort has been recently discontinued, as enzyme induction effects can persist for weeks
- Watch for signs of lithium toxicity or instability during any transition period
- Consider evidence-based alternatives: If augmentation of lithium is needed, guideline-supported options include adding an antidepressant with established efficacy 9
Common Pitfalls to Avoid
- Assuming herbal products are safe: St. John's wort is listed only as a dietary supplement by the FDA, not as a drug, which may lead patients to underestimate interaction risks 6
- Failing to ask about herbal supplements: Patients may not volunteer information about St. John's wort use unless specifically asked
- Underestimating interaction duration: CYP3A4 induction effects can persist for 1-2 weeks after discontinuing St. John's wort 7
The combination of lithium's narrow therapeutic index 4, St. John's wort's potent enzyme induction properties 1, 2, and the risk of serotonergic interactions 3, 7 makes this combination unsafe for clinical use.